Response to NICE draft guidance on two breast cancer drugs

Breakthrough respond to NICE draft guidance which proposes to advise the NHS that lapatinib or trastuzumab with aromatase inhibitors should not be prescribed for a particular type and stage of breast cancer.

15 Feb

    • Digg
    • Delicious
    • Google
  • Print it

Dr Sarah Rawling, Head of Policy and Public Health, says,

“There is a real need for more targeted and effective treatment options for this small group of breast cancer patients. It’s vital to find the right drug combinations for the right patients and we are disappointed that NICE are unable to recommend these treatments. It’s important to remember that this is draft guidance and we’ll continue to work with NICE. 

We encourage anyone who is concerned about their treatment options to speak to their doctor.”